Moneycontrol

Moneycontrol PRO

HomeNewsAlinia

Alinia

Jump to

See Q2 better than Q1; US biz growth in 25-30% range: Lupin

According to Kamal Sharma, Lupin should perform better in Q2 than Q1 and eyes double digit growth as against virtually no growth in Q1.
Lupin in licensing pact with US-based Romark Laboratories

Lupin will get exclusive rights to distribute and market Alinia for oral suspension, a drug used to treat diarrhea caused by Cryptosporidium and Giardia, two most common protozoal causes of diarrhea.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347